Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP
4.6 (686) · $ 5.99 · In stock
See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.
PDF) Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Significant weight loss
Diabetes Canada Clinical Practice Guidelines
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3 - ScienceDirect
Ozempic® vs. Trulicity®: SUSTAIN 7 Clinical Trial Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg
Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update - ScienceDirect
A1C Data, BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg
Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. - Abstract - Europe PMC
Survey to Specify SGLT2 Inhibitor Choice in T2DM Management, Ghosal
Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care - ScienceDirect
Applying Recent A1C Recommendations in Clinical Practice
